Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 7,179,849 |
|
|||||
| News | - | ||||||
| Day High | 63.00 | Low High |
|||||
| Day Low | 56.08 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| CRISPR Therapeutics AG | CRSP | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -4.63 | -7.18% | 59.9061 | 12:58:52 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 62.95 | 56.08 | 63.00 | 64.54 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 91,233 | 7,179,849 | US$ 59.56 | US$ 427,651,120 | - | 37.55 - 76.97 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 12:58:52 | 1 | US$ 59.9312 | USD |
CRISPR Therapeutics (CRSP) Options Flow Summary
CRISPR Therapeutics AG Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.76B | 79.43M | - | 1.2M | -650.18M | -8.19 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CRISPR Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/08/2023 | 15:11 | Dow Jones News | Bluebird Bio Shares Slide 41% on Black-Box Label, Higher.. |
| 12/08/2023 | 12:16 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/08/2023 | 11:52 | Business Wire | Vertex and CRISPR Therapeutics Announce US FDA Approval of.. |
| 12/08/2023 | 10:46 | Dow Jones News | CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in.. |
| 12/04/2023 | 15:26 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/04/2023 | 15:15 | GlobeNewswire Inc. | CRISPR Therapeutics Announces Updates to Immuno-Oncology.. |
| 11/16/2023 | 06:21 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/16/2023 | 00:45 | Business Wire | Vertex and CRISPR Therapeutics Announce Authorization of.. |
| 11/06/2023 | 15:42 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/06/2023 | 15:33 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/06/2023 | 15:15 | GlobeNewswire Inc. | CRISPR Therapeutics Provides Business Update and Reports.. |
| 11/06/2023 | 04:01 | GlobeNewswire Inc. | CRISPR Therapeutics Announces Preclinical Data at the.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRSP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 69.10 | 76.97 | 56.08 | 66.78 | 5,295,187 | -9.19 | -13.31% |
| 1 Month | 52.03 | 76.97 | 48.5501 | 66.63 | 3,784,434 | 7.88 | 15.14% |
| 3 Months | 50.33 | 76.97 | 37.55 | 56.82 | 2,298,125 | 9.58 | 19.03% |
| 6 Months | 61.76 | 76.97 | 37.55 | 55.83 | 1,613,278 | -1.85 | -3.0% |
| 1 Year | 49.20 | 76.97 | 37.55 | 54.31 | 1,425,275 | 10.71 | 21.76% |
| 3 Years | 154.18 | 220.21 | 37.55 | 85.97 | 1,520,387 | -94.27 | -61.15% |
| 5 Years | 35.93 | 220.21 | 21.65 | 79.82 | 1,256,203 | 23.98 | 66.73% |
CRISPR Therapeutics Description
| CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. |
